{
    "clinical_study": {
        "@rank": "161398", 
        "arm_group": {
            "arm_group_label": "BL-8040 + Ara-C", 
            "arm_group_type": "Experimental", 
            "description": "Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (\"monotherapy period\") over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy (\"combined period\") over 5 days. During the \"combined period,\" BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days  and will not be escalated."
        }, 
        "brief_summary": {
            "textblock": "The goal of this clinical research study is to learn if BL-8040 in combination with\n      cytarabine (Ara-C) can help to control the disease in patients with Acute Myeloid Leukemia\n      (AML) that has relapsed or did not respond adequately to previous treatment.  The safety of\n      the study drug combination will also be studied."
        }, 
        "brief_title": "Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Open-label, multicenter, phase IIa, dose escalating study in subjects with\n      relapsed/refractory AML, defined according to WHO criteria (1), including subjects who\n      failed chemotherapy only and those who failed previous Autologous Stem Cell Transplantation\n      (ASCT) / Allogeneic Stem Cell Transplantation (AlloSCT), provided at least 6 months have\n      passed from transplant.\n\n      Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (\"monotherapy\n      period\") over two days (one injection per day) followed by concurrent administration of\n      BL-8040 with standard salvage chemotherapy (\"combined period\") over 5 days. During the\n      \"combined period,\" BL-8040 will be administered 4 hours prior to chemotherapy. The\n      chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age),\n      administered intravenously (IV) over 3 hours, for 5 days  and will not be escalated.\n\n      The first part of the study (Part 1) will include escalating dose groups and be considered\n      the 'escalation phase'. Five potential dose levels (see Table 1) will be investigated\n      starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying\n      this study design, the first cohort of 3 patients will be treated at dose level 1 and\n      evaluated for dose escalation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult men and women subjects aged 18 to 75, inclusive.\n\n          2. Confirmed diagnosis of relapsed/refractory AML (WHO criteria) Refractory subjects, up\n             to second consecutive salvage . Relapsed subjects including first and second relapse.\n\n          3. AML relapse > 6 months since autologous or allogeneic stem cell transplantation,\n             provided they are in first or second relapse and:\n\n             No active graft-versus-host disease (GVHD > grade 1). No treatment with high dose\n             steroids for GVHD (up to 20 mg Prednisolone or equivalent, Appendix G). No treatment\n             with immunosuppressive drugs with the exception of low dose cyclosporine and\n             tacrolimus (blood levels of 0.5-0.6 \u00b5g/mL).\n\n          4. Clinical laboratory values should be as follows:\n\n             WBC < 30,000/mL Blasts in PB \u2264 20,000. Treatment with Hydroxyurea is permitted up to\n             24 hrs prior to BL-8040 administration to achieve blast counts < 20,000 prior to\n             enrollment. Creatinine < 1.3 mg/dL; if Creatinine is > 1 mg/dL the Creatinine\n             clearance should be > 40 mL/min as calculated using the Cockcroft-Gault formula.\n\n          5. Women of childbearing potential and all men must agree to use an approved form of\n             contraception (e.g. oral, transdermal patch, implanted contraceptives, intrauterine\n             device, diaphragm, condom, abstinence or surgical sterility) prior to study entry and\n             for the duration of study participation through 30 days after the last dose of\n             BL-8040. Confirmation that female subjects are not pregnant must be established by a\n             negative serum \u03b2-human chorionic gonadotropin (\u03b2-hCG) pregnancy test result obtained\n             during screening. Pregnancy testing is not required for post-menopausal or surgically\n             sterilized women.\n\n          6. Subject is able and willing to comply with the requirements of the protocol.\n\n          7. Subject is able to voluntarily provide written informed consent.\n\n        Exclusion Criteria:\n\n          1. Administration of conventional chemotherapy within 2 weeks of enrollment date. In the\n             event that subjects have received chemotherapy > 2 weeks from the date of enrollment,\n             they may be included provided they have recovered from the associated\n             non-hematological toxicities to \u2264 grade 1.\n\n          2. Life expectancy of \u2264 2 months.\n\n          3. Known allergy or hypersensitivity to any of the test compounds, materials or\n             contraindication to test product.\n\n          4. Use of investigational device or agents within 2 weeks of enrollment date.\n\n          5. Low Performance Status (ECOG > 2; Appendix E).\n\n          6. O2 saturation < 92% (on room air), evidence of TLS > grade 2 (according to the\n             Cairo-Bishop criteria (3)) or leukostasis (2).\n\n          7. Abnormal liver function tests:\n\n             Serum aspartate transaminase (AST/SGOT) or alanine transaminase ( ALT/SGPT) 2 x upper\n             limit of normal (ULN). Serum bilirubin. Total bilirubin > 2.0 mg/dL (34 \u00b5mol/L),\n             conjugated bilirubin > 0.8 mg/dL.\n\n          8. Left ventricular ejection fraction < 40 %.\n\n          9. History of myocardial infarction or cerebrovascular accident within 6 months of\n             enrollment date.\n\n         10. Presence of active, uncontrolled infection.\n\n         11. Known central nervous system disease (e.g., Alzheimer's disease).\n\n         12. Acute promyelocytic leukemia.\n\n         13. Exposure to high dose Ara-C  within 6 months of enrollment.\n\n         14. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or\n             psychiatric illness which could place him/her at unacceptable risk, including, but\n             not limited to:\n\n             Subject has been diagnosed or treated for another malignancy within 3 years of\n             enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer\n             after curative therapy A co-morbid condition which, in the view of the Investigators,\n             renders the subject at high risk from treatment complications.\n\n         15. Female subjects who are pregnant or breastfeeding.\n\n         16. Prior clinically significant grade 3-4 non-hematological toxicity to high dose Ara-C\n             or grade \u2265 2 of neurological toxicity.\n\n         17. Seropositive for HIV antibodies (HIV1 and HIV2), Hepatitis C antibody (Hep C Ab) or a\n             Hepatitis B carrier (positive for Hepatitis B surface antigen [HBsAg]).\n\n         18. Unable to comply with study requirements in the opinion of the Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838395", 
            "org_study_id": "BL-8040.01"
        }, 
        "intervention": [
            {
                "arm_group_label": "BL-8040 + Ara-C", 
                "description": "IV", 
                "intervention_name": "Ara-C", 
                "intervention_type": "Drug", 
                "other_name": "cytarabine"
            }, 
            {
                "arm_group_label": "BL-8040 + Ara-C", 
                "description": "SC", 
                "intervention_name": "BL-8040", 
                "intervention_type": "Drug", 
                "other_name": "BL8040"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cytarabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AML", 
            "Acute Myeloid Leukemia", 
            "Relapsed Acute Myeloid Leukemia", 
            "Refractory Acute Myeloid Leukemia"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "j-altman@northwestern.edu", 
                    "last_name": "Jessica Altman, MD", 
                    "phone": "312-503-1817"
                }, 
                "contact_backup": {
                    "email": "s-duffey@northwestern.edu", 
                    "last_name": "Sara Duffey", 
                    "phone": "312-695-1102"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University-Robert H. Lurie Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jessica Altman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "TallmanM@mskcc.org", 
                    "last_name": "Martin Tallman, Prof", 
                    "phone": "212-639-3842"
                }, 
                "contact_backup": {
                    "email": "faltag@mskcc.org", 
                    "last_name": "Gary Falta", 
                    "phone": "646-497-9152"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Martin Tallman, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gborthak@mdanderson.org", 
                    "last_name": "Gautam Borthakur, MD"
                }, 
                "contact_backup": {
                    "email": "mengland@mdanderson.org", 
                    "last_name": "Melodie England", 
                    "phone": "713-563-6700"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Gautam Borthakur, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "y_ofran@rambam.health.gov.il", 
                    "last_name": "Yishai Ofran, MD"
                }, 
                "contact_backup": {
                    "email": "l_dan@rambam.health.gov.il", 
                    "last_name": "Limor Dan", 
                    "phone": "972-4-854-2547"
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31096"
                    }, 
                    "name": "Rambam Medical Center"
                }, 
                "investigator": {
                    "last_name": "Yishai Ofran, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rowe@rambam.health.gov.il", 
                    "last_name": "Jacob M Rowe, MD"
                }, 
                "contact_backup": {
                    "email": "tamig@szmc.org.il", 
                    "last_name": "Tami Granot", 
                    "phone": "972-52-8372079"
                }, 
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "91031"
                    }, 
                    "name": "Shaare Zedek Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jacob M Rowe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dbyehuda@hadassah.org.il", 
                    "last_name": "Dina Ben-Yehuda, MD"
                }, 
                "contact_backup": {
                    "email": "nuritb@hadassah.org.il", 
                    "last_name": "Nurit Ben-Shmuel", 
                    "phone": "972-2-6776687"
                }, 
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "91120"
                    }, 
                    "name": "Hadassah University Hospital"
                }, 
                "investigator": {
                    "last_name": "Dina Ben- Yehuda, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Amichai.shimoni@sheba.health.gov.il", 
                    "last_name": "Amichai Shimoni, MD"
                }, 
                "contact_backup": {
                    "email": "Andrea.Klein@sheba.health.gov.il", 
                    "last_name": "Andrea Tabachnik, RN", 
                    "phone": "972-50-7624454"
                }, 
                "facility": {
                    "address": {
                        "city": "Ramat Gan", 
                        "country": "Israel", 
                        "zip": "52621"
                    }, 
                    "name": "Chaim Sheba Medical Center"
                }, 
                "investigator": {
                    "last_name": "Amichai Shimoni, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nadavsarid@gmail.com", 
                    "last_name": "Nadav Sarid, MD", 
                    "phone": "972 3-697-3577"
                }, 
                "contact_backup": {
                    "email": "oritb@tlvmc.gov.il", 
                    "last_name": "Orit Baram, SC", 
                    "phone": "972 3-697-3577"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "Tel-Aviv Sourasky Medical Center"
                }, 
                "investigator": {
                    "last_name": "Nadav Sarid, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Israel"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA", 
        "other_outcome": {
            "description": "To assess additional pharmacodynamic parameters relevant to CXCR4 inhibition by CXCR4 receptor occupancy", 
            "measure": "Pharmacodynamic parameters", 
            "safety_issue": "No", 
            "time_frame": "After end of study- an expected average of 6 weeks."
        }, 
        "overall_official": {
            "affiliation": "BioLineRx, Ltd.", 
            "last_name": "Arnon Aharon, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Israel: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "General safety: Vital signs (oral temperature, blood pressure, pulse rate, respiratory rate and O2 saturation), 12-lead ECG and physical examination.\nToxicity according to the latest version of NCI-CTCAE (currently V4.03, refer to )\nfor AEs and clinical laboratory profile as follows: Screening: record and report screening results, however not considered treatment emergent AEs.\nThroughout the study: record and report all AEs and SAEs according to GCP.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "\"participants will be followed for the duration of hospital stay and the follow up period, an expected average of 6 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838395"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The outcome will be measured by response rates as assessed at final Bone Marrow evaluation based on Cheson 2003 criteria.", 
                "measure": "Clinical efficacy", 
                "safety_issue": "No", 
                "time_frame": "Final Bone Marrow evaluation -Between day 20 and day 44"
            }, 
            {
                "description": "Change in leukemic cell apoptosis in Peripheral Blood  and Bone Marrow.", 
                "measure": "Apoptotic effect", 
                "safety_issue": "No", 
                "time_frame": "Final evaluation- between day 20 and day 44"
            }, 
            {
                "description": "Mobilization of AML blasts from the bone marrow to the peripheral blood (PB) by cell counting", 
                "measure": "Mobilization", 
                "safety_issue": "No", 
                "time_frame": "Final evaluation- between day 20 and day 44"
            }, 
            {
                "description": "Cmax - maximum BL-8040 plasma concentration\nTmax - time to reach the maximum BL-8040 plasma concentration\nAUC0-t - Area under the BL-8040 plasma concentration-time curve  AUC0-\u221e - Area under the BL-8040 plasma concentration-time curve\n\u03bbz - elimination rate constant, determined by linear regression t1/2 - terminal elimination half-life, defined as 0.693/\u03bbz", 
                "measure": "Pharmacokinetic profile", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to day 7"
            }
        ], 
        "source": "BioLineRx, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioLineRx, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}